Nabriva Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Nabriva Therapeutics (NASDAQ: NBRV) announced that CEO Ted Schroeder will give a company overview and business update at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nabriva Therapeutics (NASDAQ: NBRV) announced that CEO Ted Schroeder will give a company overview and business update at the H.C. Wainwright 24th Annual Global Investment Conference. This event is set for September 12-14, 2022, during which management will host investor meetings.
Nabriva is focused on developing innovative anti-infective agents. Their FDA-approved product, XENLETA®, is the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia, while they are also developing CONTEPO™ for complicated urinary tract infections.
Details
News Market Reaction – NBRV
The recorded move for NBRV in the trading session of this news was -4.22%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DUBLIN, Ireland and FORT WASHINGTON, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Officer at Nabriva, will provide a company overview and business update at the H.C. Wainwright 24th Annual Global Investment Conference. Management will also host investor meetings September 12-14, 2022.
About Nabriva Therapeutics plc
Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA® (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP). Nabriva Therapeutics is also developing CONTEPO™ (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis. Nabriva entered into an exclusive agreement with subsidiaries of Merck & Co. Inc., Kenilworth, N.J., USA to market, sell and distribute SIVEXTRO® (tedizolid phosphate) in the United States and certain of its territories.
CONTACTS:
For Investors
Kim Anderson
Nabriva Therapeutics plc
ir@nabriva.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.